BioMarin Pharmaceutical Inc. Reports Strong Third Quarter 2026 Results with Significant Revenue Growth
BioMarin Reports Robust Third Quarter 2026 Results
On November 2, 2026, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced its financial results for the third quarter ended September 30, 2026. The company reported total revenues of $1.025 billion, reflecting a remarkable 32% increase year-over-year (Y/Y). This growth can be attributed primarily to a 44% rise in revenue from metabolic conditions and a 12% increase in skeletal conditions Y/Y.
The revenue milestone marks the first time BioMarin has surpassed the $1 billion mark within a single quarter, as noted by the company's President and CEO, Alexander Hardy. He emphasized that this achievement is a result of a more diversified portfolio, particularly following the recent acquisition of Amicus Therapeutics, which has significantly enhanced the company’s offerings.
Continued Innovation and Pipeline Expansion
BioMarin has made strides in innovation, announcing the addition of a new investigational treatment for Fabry disease to its portfolio. This treatment aims to be the first subcutaneous enzyme replacement therapy for this condition and is currently undergoing a global Phase 1/2 clinical study.
On the regulatory front, the U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 30, 2027, for VOXZOGO, a drug aimed at treating hypochondroplasia, which underscores BioMarin’s commitment to developing therapies for rare genetic diseases. The company is also looking to expand the use of VOXZOGO, with the FDA reviewing its application for full approval in children with achondroplasia, where data on long-term safety and efficacy are under consideration.
Financial Highlights for Q3 2026
The company's robust performance is further highlighted by the following key points:
- - Metabolic Condition Revenue Growth: Driven by the integration of products like GALAFOLD and POMBILITI + OPFOLDA, metabolic conditions revenue saw an impressive 44% increase Y/Y in Q3, complementing a 26% rise year-to-date.
- - Patient Expansion: The number of patients receiving therapies for metabolic conditions has increased significantly, with GALAFOLD and the POMBILITI + OPFOLDA regimen treating approximately 13% and 69% more patients, respectively.
- - VOXZOGO Revenue: The revenue from VOXZOGO increased by 12% Y/Y, with a notable 17% rise in the number of treated children globally.
Despite these successes, BioMarin also reported a GAAP net loss of $123 million for the third quarter, compared to a $31 million loss during the same period in the previous year. This increase in net loss is primarily linked to acquisition-related costs, including intangibles amortization and the financial implications of integrating new operations from Amicus.
Looking Ahead: Strategic Directions
The company has revised its full-year guidance for 2026 to reflect uncertainties in order timing and the impact of the integrated research and development charges stemming from its acquisitions. BioMarin remains committed to building sustainable growth, driven by a strong pipeline of innovative therapies targeting rare genetic conditions.
As 2027 approaches, BioMarin expects to enter a pivotal phase in its growth trajectory, poised to deliver on its therapeutic innovations while ramping up its operational efficiencies in the aftermath of significant acquisitions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.